Ioannis M. Koukourakis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ioannis M. Koukourakis has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Michael Ioannis Koukourakis
Department of Radiotherapy/Oncology, School of Medicine, Democritus University of Thrace, 68100 Alexandroupolis, Greece
2 shared publications - Alexandra Giatromanolaki
Department of Pathology, School of Medicine, Democritus University of Thrace, 68100 Alexandroupolis, Greece
1 shared publication - Anna Zygogianni
Radiation Oncology Unit, Aretaieion Hospital, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece
1 shared publication - Christina Yfanti
Department of Pathology, Hippokratio General Hospital of Thessaloniki, Thessaloniki, Greece
1 shared publication - Christos Kalaitzis
Department of Urology, Democritus University of Thrace, 68100 Alexandroupolis, Greece
1 shared publication - Georgios Maravelis
2nd Department of Radiation Oncology, Metropolitan Hospital, Neo Faliro, 18547 Piraeus, Greece
1 shared publication
Latest Publications
- Open Access
Lactate Dehydrogenase-5 and Tumor-Infiltrating Lymphocytes in Prostate Cancer Patients Undergoing Radical Hypofractionated Radiotherapy
Background/Objectives: Aerobic glycolysis is a standard mechanism that cancer cells use to support their anabolic processes. Lactate and proton production, byproducts of this LDHA-catalyzed transformation of pyruvate, may contribute to acidifying the tumor microenvironment and to repressing the cytotoxic activity of anti-tumor immune cells. Prostate cancer radiotherapy outcome could be diminished by cancer cell metabolism and immunosuppression. Methods: The tumor infiltrating lymphocyte (TIL) density was assessed in 110 prostate adenocarcinoma biopsies from patients treated with radical radiotherapy. Immunohistochemistry was performed to evaluate LDH5 expression by cancer cells (encoded by the LDHA gene). Results: Higher tumor stages (T3 and T4) were associated with lower TIL density (p = 0.02). Approximately half of the patients (51%) displayed strong LDH5 cancer cell expression, which was linked with advanced T-stage and higher Gleason scores (p = 0.05 and p = 0.01, respectively). High LDH5 expression was significantly correlated with low TIL density (p ≤ 0.0004). In univariate analysis, high LDH5 and low TIL density were associated with poor biochemical relapse-free survival (BRFS) (p ≤ 0.006). In multivariate analysis, TIL density, but not LDH5, was an independent predictor of BRFS (p = 0.03). Conclusions: LDH5 overexpression is associated with low tumor lymphocytic infiltration. Stratifying prostate carcinomas according to LDH5/TIL density identifies a group of patients with low TIL density and high LDH5 expression, who have a higher risk of tumor relapse. Targeting glycolysis to disrupt cancer cell metabolism offers an interesting research area for prostate cancer therapy.
Open AccessLactate Dehydrogenase-5 and Tumor-Infiltrating Lymphocytes in Prostate Cancer Patients Undergoing Radical Hypofractionated Radiotherapy
Background/Objectives: Aerobic glycolysis is a standard mechanism that cancer cells use to support their anabolic processes. Lactate and proton production, byproducts of this LDHA-catalyzed transformation of pyruvate, may contribute to acidifying the tumor microenvironment and to repressing the cytotoxic activity of anti-tumor immune cells. Prostate cancer radiotherapy outcome could be diminished by cancer cell metabolism and immunosuppression. Methods: The tumor infiltrating lymphocyte (TIL) density was assessed in 110 prostate adenocarcinoma biopsies from patients treated with radical radiotherapy. Immunohistochemistry was performed to evaluate LDH5 expression by cancer cells (encoded by the LDHA gene). Results: Higher tumor stages (T3 and T4) were associated with lower TIL density (p = 0.02). Approximately half of the patients (51%) displayed strong LDH5 cancer cell expression, which was linked with advanced T-stage and higher Gleason scores (p = 0.05 and p = 0.01, respectively). High LDH5 expression was significantly correlated with low TIL density (p ≤ 0.0004). In univariate analysis, high LDH5 and low TIL density were associated with poor biochemical relapse-free survival (BRFS) (p ≤ 0.006). In multivariate analysis, TIL density, but not LDH5, was an independent predictor of BRFS (p = 0.03). Conclusions: LDH5 overexpression is associated with low tumor lymphocytic infiltration. Stratifying prostate carcinomas according to LDH5/TIL density identifies a group of patients with low TIL density and high LDH5 expression, who have a higher risk of tumor relapse. Targeting glycolysis to disrupt cancer cell metabolism offers an interesting research area for prostate cancer therapy.
- Open Access
- 17 June 2026
- Published by MDPI AG in Current Oncology
- Vol. 33 (6) , 364
Metabolism and Immunity-Adapted Radiotherapy (M.I.A.R): A Conceptual Framework for Overcoming the Therapeutic Plateau in Clinical Radiotherapy
Despite technological advances in radiation therapy (RT), improvements in locoregional control of locally advanced disease remain limited, indicating a plateau in RT effectiveness. It is becoming increasingly clear that RT occurs within a dynamic metabolic microenvironment that merges oncogenic activity with metabolic and immune interactions. This includes responses to oxidative stress, regulation of cell death and survival signals, energy metabolism, protein synthesis, autophagy of molecules and organelles, and ultimately, the anti-tumor immune response. Each tumor, regardless of its histology, maintains a unique molecular and microenvironmental identity that influences its response to RT. Furthermore, RT acts as a cellular stressor that activates responses in cancer and stromal cells, impacting clinical outcomes. The concept of Metabolism and Immunity Adaptive Radiotherapy (M.I.A.R) recognizes that RT success depends not only on radiation dose and distribution but mainly on key interventions that alter and influence the biological environment before, during, and after therapy. It highlights the importance of an initial diagnostic workup, which is achievable with current tools, to identify tumor-specific oncogenes, metabolic, and immune profiles. Within the context of M.I.A.R., effective RT requires tumor preconditioning combined with concurrent use of drugs, including metabolism-targeting agents, to increase tumor sensitivity to radiation. Post-RT metabolic and immune interventions are essential for complete tumor eradication. This involves combining existing oncogene-targeting therapies with available immune treatments, supported by low-toxicity modulating drugs/agents with demonstrated preclinical activity against specific molecular and microenvironmental features. Overall, while MIAR remains a theoretical approach, existing preclinical and recent clinical data, e.g., those exploiting tumor hypoxia and re-oxygenation status, or post-RT immunotherapy, strongly support further dedicated investigation.
- 17 June 2026
- Published by MDPI AG in Current Oncology
- Vol. 33 (6) , 364
Open AccessMetabolism and Immunity-Adapted Radiotherapy (M.I.A.R): A Conceptual Framework for Overcoming the Therapeutic Plateau in Clinical Radiotherapy
Despite technological advances in radiation therapy (RT), improvements in locoregional control of locally advanced disease remain limited, indicating a plateau in RT effectiveness. It is becoming increasingly clear that RT occurs within a dynamic metabolic microenvironment that merges oncogenic activity with metabolic and immune interactions. This includes responses to oxidative stress, regulation of cell death and survival signals, energy metabolism, protein synthesis, autophagy of molecules and organelles, and ultimately, the anti-tumor immune response. Each tumor, regardless of its histology, maintains a unique molecular and microenvironmental identity that influences its response to RT. Furthermore, RT acts as a cellular stressor that activates responses in cancer and stromal cells, impacting clinical outcomes. The concept of Metabolism and Immunity Adaptive Radiotherapy (M.I.A.R) recognizes that RT success depends not only on radiation dose and distribution but mainly on key interventions that alter and influence the biological environment before, during, and after therapy. It highlights the importance of an initial diagnostic workup, which is achievable with current tools, to identify tumor-specific oncogenes, metabolic, and immune profiles. Within the context of M.I.A.R., effective RT requires tumor preconditioning combined with concurrent use of drugs, including metabolism-targeting agents, to increase tumor sensitivity to radiation. Post-RT metabolic and immune interventions are essential for complete tumor eradication. This involves combining existing oncogene-targeting therapies with available immune treatments, supported by low-toxicity modulating drugs/agents with demonstrated preclinical activity against specific molecular and microenvironmental features. Overall, while MIAR remains a theoretical approach, existing preclinical and recent clinical data, e.g., those exploiting tumor hypoxia and re-oxygenation status, or post-RT immunotherapy, strongly support further dedicated investigation.